A phase I trial of hypoxoside as an oral prodrug for cancer therapy : absence of toxicity

Simple item page
dc.contributor.authorSmit, B. J.en_ZA
dc.contributor.authorAlbrecht, C. F.en_ZA
dc.contributor.authorLiebenberg, R. W.en_ZA
dc.contributor.authorKruger, P. B.en_ZA
dc.contributor.authorFreestone, M.en_ZA
dc.contributor.authorGouws, L.en_ZA
dc.contributor.authorTheron, E.en_ZA
dc.contributor.authorBouic, P. J. D.en_ZA
dc.contributor.authorEtsebeth, S.en_ZA
dc.contributor.authorVan Jaarsveld, P. P.en_ZA
dc.date.accessioned2011-03-18T14:57:11Z
dc.date.available2011-03-18T14:57:11Z
dc.date.issued1995
dc.descriptionCITATION: Smit, B. J. 1995. A phase I trial of hypoxoside as an oral prodrug for cancer therapy : absence of toxicity. South African Medical Journal, 85:865-870.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractObjective. To assess the toxicity of hypoxoside taken orally by 24 patients with lung cancer. Design. Open study with patients taking 1 200 - 3 200 mg standardised Hypoxis plant extract (200 mg capsules) per day divided in 3 doses in order to maintain metabolite blood levels near 100 μg/ml. Participants and setting. Patients with histologically proven squamous, large-cell or adenocarcinoma were hospitalised initially at the radiation oncology ward, Karl Bremer Hospital, Bellville, W. Cape. Thereafter they returned every 2 weeks for full clinical examinations. Methods. Routine biochemical and haematological measurements were done. Patients underwent regular full clinical examinations including radiographs and computed tomography scanning according to the discretion of the principal investigator. Results. Nineteen patients on hypoxoside therapy survived for an average of 4 months with progression of their primary tumours and metastases, while 5 survived for more than a year. One of them survived for 5 years and histological examination of the primary lesion showed absence of cancer. No toxic effects, in clinical examinations or biochemical or haematological measurements, were found that could be ascribed to the ingestion of hypoxoside. Only one occasion of possible drug intolerance, with anxiety, nausea, vomiting and diarrhoea, was noted. Conclusion. The absence of toxicity warrants further investigation of hypoxoside as an oral prodrug, especially in patients with slow-growing necrotising tumours that are inoperable and have high concentrations of β-glucuronidase and sulphatase as high sensitivity for rooperol.
dc.description.versionPublisher’s version
dc.format.extent6 pages
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/7249
dc.language.isoen
dc.publisherHealth & Medical Publishing Group
dc.rights.holderSouth African Medical Journal
dc.subjectCancer -- Treatmenten_ZA
dc.titleA phase I trial of hypoxoside as an oral prodrug for cancer therapy : absence of toxicityen_ZA
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
smit_phase_1995.pdf
Size:
3.89 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
Collections
Research Articles (Radiation Oncology)